Optimization of native E. coli-asparaginase therapy in standard risk-group children with acute lymphoblastic leukemia treated by the ALL-MB 2002 protocol

M. Yu. Goroshkova; Горошкова М. Ю.; Yu. V. Rumyantseva; Румянцева Ю. В.; O. V. Aleinikova; Алейникова О. В.; S. A. Dudkin; Дудкин С. А.; L. G. Fechina; Фечина Л. Г.; A. V. Shamardina; Шамардина А. В.; O. V. Streneva; Стренева О. В.; K. L. Kondratchik; Кондратчик К. Л.; L. M. Minkina; Минкина Л. М.; E. S. Lapotentova; Лапотентова Е. С.; E. V. Inyushkina; Инюшкина Е. В.; O. B. Kozlova; Козлова О. Б.; E. V. Zhukovskaya; Жуковская Е. В.; O. P. Khlebnikova; Хлебникова О. П.; E. V. Basharova; Башарова Е. В.; V. N. Timofeeva; Тимофеева В. Н.; G. P. Pavlova; Павлова Г. П.; V. D. Zlobina; Злобина В. Д.; O. A. Utrobina; Утробина О. А.; E. S. Banshchikova; Банщикова Е. С.; K. S. Aslanyan; Асланян К. С.; E. V. Kondakova; Кондакова Е. В.; E. V. Tselousova; Целоусова Е. В.; N. V. Myakova; Мякова Н. В.; T. V. Turobova; Туробова Т. В.; O. V. Ryskal; Рыскаль О. В.; O. Yu. Fuks; Фукс О. Ю.; V. V. Lebedev; Чипсанова О. Ю.; N. F. Chipsanova; Варфоломеева С. Р.; S. R. Varfolomeeva; Лебедев В. В.; A. I. Karachunsky; Карачунский А. И.

doi:10.17650/1818-8346-2008-0-3-25-33

Optimization of native E. coli-asparaginase therapy in standard risk-group children with acute lymphoblastic leukemia treated by the ALL-MB 2002 protocol

Authors: Goroshkova M.Y.¹, Rumyantseva Y.V.², Aleinikova O.V.³, Dudkin S.A.¹, Fechina L.G.⁴, Shamardina A.V.⁵, Streneva O.V.⁴, Kondratchik K.L.⁶, Minkina L.M.⁷, Lapotentova E.S.³, Inyushkina E.V.⁸, Kozlova O.B.⁹, Zhukovskaya E.V.¹⁰, Khlebnikova O.P.⁴, Basharova E.V.¹⁰, Timofeeva V.N.¹⁰, Pavlova G.P.¹¹, Zlobina V.D.⁹, Utrobina O.A.⁹, Banshchikova E.S.¹², Aslanyan K.S.¹⁰, Kondakova E.V.¹⁰, Tselousova E.V.¹³, Myakova N.V.¹⁴^,15, Turobova T.V.¹⁰, Ryskal O.V.¹⁰, Fuks O.Y.²^,6, Lebedev V.V.¹⁰, Chipsanova N.F.¹⁶, Varfolomeeva S.R.², Karachunsky A.I.²
Affiliations:
1. Clinical Children Hospital №4
2. Federal Research Centre of Pediatric Hematology, Oncology and Immunology
3. Republic Centre for Paediatric Oncology and Haematology
4. Regional Centre for Paediatric Oncology and Haematology
5. Regional Clinical Children Hospital
6. Morozov Children Clinical Hospital
7. Clinical Children Hospital
8. Moscow District Oncology Dispanser
9. Regional Clinical Hospital
10. Regional Children Clinical Hospital
11. Republic Children Clinical Hospital
12. Republic Hospital №1 — National Medicine Centre
13. Kirov Research Centre of Hematology and Transfusiology
14. Federal Research Centre of Pediatric Hematology
15. Russian Children Clinical Hospital
16. Regional cardiological dispanser
Issue: No 3 (2008)
Pages: 25-33
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT
Published: 24.08.2008
URL: https://oncohematology.abvpress.ru/ongm/article/view/722
DOI: https://doi.org/10.17650/1818-8346-2008-0-3-25-33
ID: 722

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The paper presents the results of a multicenter randomized study of two-dose COLI-ASP regimens in therapy of consolidation of standard risk-group (SRG) children and adolescents with acute lymphoblastic leukemia (ALL) treated by the ALL-MB-2002 protocol. The principal aim of the study was to elucidate whether the dose of COLI-ASP might be reduced without losing the efficiency of therapy. The analysis covered primary ALL patients notified at 36 clinics of Russia and Belarus, enrolled for the study in the period of May 1, 2002, to October 10, 2006. Out of 819 patients to be examined, 414 received COLI-ASP in a dose of 10,000 U/m2 (a control group), and 405 children took it in a dose of 5,000 U/m2 (a study group). No statistically significant differences were found between the patients in gender, age, baseline leukocytosis, and spleen size. The study showed no statistically and clinically significant differences in event-free, overall, and relapse-free survival (EFS, OS, and RFS, respectively) and relapse rates with the use of two-dose COLI-ASP regimens. However, in the control group, the death rate in remission was twice greater than that in the study group (p = 0.02). Detailed analysis of the outcomes of therapy in some subgroups revealed no differences between the control and study groups. The Cox multiple regression analysis has indicated that the factors influencing EFS and RFS are the baseline sizes of the spleen, baseline leukocytosis, age, and a response to treatment in the period of induction, rather than the dose of E. coli asparaginase. The authors have also found that among the SRG patients, there is a subgroup of patients without risk factors, in whom the reduction in the COLI-ASP dose may substantially increase survival rates, by lowering toxicity and mortality in remission.

Keywords

acute lymphoblastic leukemia, children, L-asparaginase, efficacy, toxicity

About the authors

M. Yu. Goroshkova

Clinical Children Hospital №4

Author for correspondence.

Novokuznetsk

Russian Federation

Yu. V. Rumyantseva

Federal Research Centre of Pediatric Hematology, Oncology and Immunology

Moscow

Russian Federation

O. V. Aleinikova

Republic Centre for Paediatric Oncology and Haematology

Minsk

Belarus

S. A. Dudkin

Clinical Children Hospital №4

Novokuznetsk

Russian Federation

L. G. Fechina

Regional Centre for Paediatric Oncology and Haematology

Yekaterinburg

Russian Federation

A. V. Shamardina

Regional Clinical Children Hospital

N. Novgorod

Russian Federation

O. V. Streneva

Regional Centre for Paediatric Oncology and Haematology

Yekaterinburg

Russian Federation

K. L. Kondratchik

Morozov Children Clinical Hospital

Moscow

Russian Federation

L. M. Minkina

Clinical Children Hospital

Vladivostok

Russian Federation

E. S. Lapotentova

Republic Centre for Paediatric Oncology and Haematology

Minsk

Belarus

E. V. Inyushkina

Moscow District Oncology Dispanser

Balaschicha

Russian Federation

O. B. Kozlova

Regional Clinical Hospital

Ivanovo

Russian Federation

E. V. Zhukovskaya

Regional Children Clinical Hospital

Chelyabinsk

Russian Federation

O. P. Khlebnikova

Regional Centre for Paediatric Oncology and Haematology

Yekaterinburg

Russian Federation

E. V. Basharova

Regional Children Clinical Hospital

Chelyabinsk

Russian Federation

V. N. Timofeeva

Regional Children Clinical Hospital

Ulyanovsk

Russian Federation

G. P. Pavlova

Republic Children Clinical Hospital

Cheboksary

Russian Federation

V. D. Zlobina

Regional Clinical Hospital

Novosibirsk

Russian Federation

O. A. Utrobina

Regional Clinical Hospital

Novosibirsk

Russian Federation

E. S. Banshchikova

Republic Hospital №1 — National Medicine Centre

Yakutsk

Russian Federation

K. S. Aslanyan

Regional Children Clinical Hospital

Rostov-on-Don

Russian Federation

E. V. Kondakova

Regional Children Clinical Hospital

Surgut

Russian Federation

E. V. Tselousova

Kirov Research Centre of Hematology and Transfusiology

Kirov

Russian Federation

N. V. Myakova

Federal Research Centre of Pediatric Hematology; Russian Children Clinical Hospital

Moscow

Russian Federation

T. V. Turobova

Regional Children Clinical Hospital

Archangelsk

Russian Federation

O. V. Ryskal

Regional Children Clinical Hospital

Perm

Russian Federation

O. Yu. Fuks

Federal Research Centre of Pediatric Hematology, Oncology and Immunology; Morozov Children Clinical Hospital

Moscow

Russian Federation

V. V. Lebedev

Regional Children Clinical Hospital

Krasnodar

Russian Federation

N. F. Chipsanova

Regional cardiological dispanser

Syktyvkar

Russian Federation

S. R. Varfolomeeva

Federal Research Centre of Pediatric Hematology, Oncology and Immunology

Moscow

Russian Federation

A. I. Karachunsky

Federal Research Centre of Pediatric Hematology, Oncology and Immunology

Moscow

Russian Federation

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register